Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genasys (GNSS) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Genasys (GNSS) over the last 16 years, with Sep 2025 value amounting to $8.0 million.

  • Genasys' Cash & Equivalents rose 61.15% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 61.15%. This contributed to the annual value of $8.0 million for FY2025, which is 61.15% up from last year.
  • According to the latest figures from FY2025, Genasys' Cash & Equivalents is $8.0 million, which was up 61.15% from $4.9 million recorded in FY2024.
  • Genasys' Cash & Equivalents' 5-year high stood at $13.2 million during FY2021, with a 5-year trough of $4.9 million in FY2024.
  • For the 3-year period, Genasys' Cash & Equivalents averaged around $7.2 million, with its median value being $8.0 million (2025).
  • In the last 5 years, Genasys' Cash & Equivalents crashed by 43.54% in 2021 and then soared by 61.15% in 2025.
  • Yearly analysis of 5 years shows Genasys' Cash & Equivalents stood at $13.2 million in 2021, then decreased by 3.27% to $12.7 million in 2022, then plummeted by 31.96% to $8.7 million in 2023, then crashed by 42.93% to $4.9 million in 2024, then surged by 61.15% to $8.0 million in 2025.